Prospectus relating to Active Biotech's rights issue published
(Thomson Reuters ONE) -
2016-11-18
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR IN ANY OTHER JURISDICTION IN
WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.
The prospectus relating to Active Biotech AB's (publ) rights issue has now been
published and is available on the company's website, www.activebiotech.com. The
prospectus can also be ordered from Active Biotech by telephone +46 (0)46
19 20 00.
For further information, please contact:
Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson(at)activebiotech.com
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam(at)activebiotech.com
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Phone +46 (0)46 19 20 00
Fax +46 (0)46 19 11 05
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, paquinimod och SILC
projects. Please visit www.activebiotech.com for more information.
Important information
This press release is not an offer to subscribe for shares in Active Biotech and
investors should not subscribe for or purchase any securities, except on the
basis of information provided in the prospectus.
This press release may not be made public, released or distributed, directly or
indirectly, in or into the United States, Australia, Japan or Canada or in any
other jurisdiction in which the distribution of this press release would be
unlawful. Further, this press release does not constitute an offer to sell new
shares, interim shares ("BTA") or subscription rights to any person in any
jurisdiction in which it is unlawful to make such offer to such person or where
such action would require additional prospectuses, registration or other
measures other than those pursuant to Swedish law. The prospectus, application
form and other documents associated with the rights issue may not be distributed
in or to any country where such distribution or the rights issue would require
such measures set forth in the preceding sentence or be in violation of the
regulations of such country.
The new shares and subscription rights have not been recommended or approved by
any United States federal or state securities commission or regulatory
authority. No new shares, BTA, subscription rights or other securities issued by
Active Biotech have been or will be registered under the U.S. Securities Act of
1933, as amended, or under the securities legislation in any state of the United
States, and may not be offered, exercised or sold in the United States absent
registration or an applicable exemption from registration requirements. There is
no intention to register any portion of the rights issue in the United States or
to conduct a public offering of securities in the United States.
The Company has not authorized any offer of the securities referred to herein to
the public in any country in the European Economic Area ("EEA") other than
Sweden. In other member states in the EEA, the securities may only be offered to
(a) any legal entity which is a qualified investor as defined in the Directive
2003/71/EC (the "Prospectus Directive"); or (b) any person falling within
Article 3(2) of the Prospectus Directive.
In the United Kingdom, this communication is only being distributed to, and is
only directed at "qualified investors" (as defined in section 86(7) of the
Financial Services and Markets Act 2000) who are (i) investment professionals
falling within the meaning of Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) persons
falling within Article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations, etc.") of the Order (all such persons together
being referred to as "relevant persons"). In the United Kingdom, any investment
or investment activity to which this communication relates is available only to,
and will be engaged in only with, relevant persons. Any person who is not a
relevant person should not take any action on the basis of this communication
and should not act or rely on it or any of its contents.
161118_Prospectus relating to Active Biotech's rights issue published:
http://hugin.info/1002/R/2057735/771080.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2016 - 15:15 Uhr
Sprache: Deutsch
News-ID 508038
Anzahl Zeichen: 5690
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 310 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prospectus relating to Active Biotech's rights issue published"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
